Equities Analysts Set Expectations for TMO Q3 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Stock analysts at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for Thermo Fisher Scientific in a research report issued to clients and investors on Thursday, February 20th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $5.80 for the quarter, up from their previous forecast of $5.73. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific’s Q4 2025 earnings at $6.67 EPS, FY2025 earnings at $23.17 EPS, Q1 2026 earnings at $6.36 EPS, Q4 2026 earnings at $6.30 EPS and FY2026 earnings at $25.55 EPS.

A number of other brokerages also recently weighed in on TMO. Royal Bank of Canada set a $693.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 31st. Bank of America lowered their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Scotiabank boosted their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research report on Monday, February 3rd. Citigroup lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research note on Friday, January 31st. Finally, Wells Fargo & Company upped their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $656.86.

Thermo Fisher Scientific Trading Up 0.6 %

Thermo Fisher Scientific stock opened at $535.55 on Monday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a market cap of $204.85 billion, a PE ratio of 32.40, a P/E/G ratio of 2.99 and a beta of 0.77. The stock’s 50 day simple moving average is $548.58 and its two-hundred day simple moving average is $566.86. Thermo Fisher Scientific has a 12 month low of $493.30 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%.

Hedge Funds Weigh In On Thermo Fisher Scientific

Institutional investors have recently modified their holdings of the business. Norges Bank purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $3,149,754,000. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 86.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company’s stock worth $1,604,338,000 after purchasing an additional 1,433,444 shares during the period. FMR LLC grew its position in Thermo Fisher Scientific by 19.7% in the 3rd quarter. FMR LLC now owns 7,877,459 shares of the medical research company’s stock valued at $4,872,761,000 after buying an additional 1,294,453 shares during the last quarter. Kovitz Investment Group Partners LLC raised its position in Thermo Fisher Scientific by 1,905.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company’s stock worth $469,889,000 after buying an additional 858,193 shares during the last quarter. Finally, Proficio Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 68,617.0% in the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company’s stock worth $396,810,000 after acquiring an additional 761,649 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,125 shares of company stock valued at $11,231,699 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.32%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.